Literature DB >> 9600354

A human vascular endothelial cell model to study angiogenesis and tumorigenesis.

J S Rhim1, W P Tsai, Z Q Chen, Z Chen, C Van Waes, A M Burger, J A Lautenberger.   

Abstract

Endothelial cell biology has recently been the subject of considerable interest in thrombosis and cancer research. However, the successful establishment of immortalized human endothelial cells which retain differentiated cell characteristics has been rare. We have successfully established immortalized human umbilical vein endothelial cells (HUVECs) by human papilloma virus (HPV)-16 E6-E7. HPV-16 E6, E7 and E6-E7 were successfully introduced into HUVEC cells. Both E6 and E7 cultures had an extended lifespan but eventually underwent senescence. E6-E7 cultures 4-5-2G, however, acquired an indefinite lifespan in culture but did not undergo malignant conversion. Telomerase activity was not detected in either E6 or E7 cultures; however, telomerase was detected in E6-E7 4-5-2G cells. The cells exhibited a 'cobblestone' morphology and developed a capillary-like tube structure upon reaching confluence. The 4-5-2G line expressed Factor VIII related antigen and took up DiI-Ac-LDL as markers of endothelial origin. The line expressed integrin subunits (alpha(v)beta3, alph(v)beta5, beta1, alpha2, alpha3, beta4 and alpha6) consistent with an endothelial origin. The higher passage of 4-5-2G line showed a similar intensity of integrin immunostaining to that of primary HUVECS. Subsequent infection of these immortal cells with the Kirsten murine sarcoma virus which contains an activated K-ras oncogene induced morphological transformation that led to the acquisition of invasion capability and neoplastic properties. Telomerase was also detected in the tumorigenic v-Ki-ras transformed cell line. These cell lines should be useful for studies of the molecular mechanisms underlying normal and neoplastic endothelial cell proliferation and migration, and might also provide an in vitro model for development of pharmacologic and gene therapy for cardiovascular thrombosis and cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9600354     DOI: 10.1093/carcin/19.4.673

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  13 in total

1.  Tumor-targeted HPMA copolymer-(RGDfK)-(CHX-A''-DTPA) conjugates show increased kidney accumulation.

Authors:  Mark P Borgman; Tomika Coleman; Rohit B Kolhatkar; Sandra Geyser-Stoops; Bruce R Line; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2008-07-18       Impact factor: 9.776

2.  Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery.

Authors:  Mark P Borgman; Omer Aras; Sandra Geyser-Stoops; Edward A Sausville; Hamidreza Ghandehari
Journal:  Mol Pharm       Date:  2009 Nov-Dec       Impact factor: 4.939

3.  Spontaneous immortalization of human dermal microvascular endothelial cells.

Authors:  Ming Jiang; Yongfen Min; Laura Debusk; Suzanne Fernandez; Douglas W Strand; Simon W Hayward; P Charles Lin
Journal:  World J Stem Cells       Date:  2010-10-26       Impact factor: 5.326

4.  Duffy antigen facilitates movement of chemokine across the endothelium in vitro and promotes neutrophil transmigration in vitro and in vivo.

Authors:  Janet S Lee; Charles W Frevert; Mark M Wurfel; Stephen C Peiper; Venus A Wong; Kimberley K Ballman; John T Ruzinski; Johng S Rhim; Thomas R Martin; Richard B Goodman
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

5.  HCMV gH/gL/UL128-131 interferes with virus entry into epithelial cells: evidence for cell type-specific receptors.

Authors:  Brent J Ryckman; Marie C Chase; David C Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-03       Impact factor: 11.205

6.  Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy.

Authors:  Mark P Borgman; Abhijit Ray; Rohit B Kolhatkar; Edward A Sausville; Angelika M Burger; Hamidreza Ghandehari
Journal:  Pharm Res       Date:  2009-02-19       Impact factor: 4.200

7.  Biological evaluation of RGDfK-gold nanorod conjugates for prostate cancer treatment.

Authors:  Adam J Gormley; Alexander Malugin; Abhijit Ray; Ryan Robinson; Hamidreza Ghandehari
Journal:  J Drug Target       Date:  2011-12       Impact factor: 5.121

8.  Temporal VEGFA responsive genes in HUVECs: Gene signatures and potential ligands/receptors fine-tuning angiogenesis.

Authors:  P Sunitha; Rajesh Raju; C K Sajil; C S Abhinand; Achuthsankar S Nair; Oommen V Oommen; V S Sugunan; P R Sudhakaran
Journal:  J Cell Commun Signal       Date:  2019-12-16       Impact factor: 5.908

9.  Tumor vascular homing endgolin-targeted radioimmunotherapy in hepatocellular carcinoma.

Authors:  Chong-Ling Duan; Gui-Hua Hou; Yan-Ping Liu; Ting Liang; Jing Song; Jian-Kui Han; Chao Zhang
Journal:  Tumour Biol       Date:  2014-08-28

Review 10.  Modeling human endothelial cell transformation in vascular neoplasias.

Authors:  Victoria W Wen; Karen L MacKenzie
Journal:  Dis Model Mech       Date:  2013-09       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.